Extramedullary relapse in a patient with acute promyelocytic leukemia: Successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies

Apostolia Maria Tsimberidou, Elihu Estey, Gary J. Whitman, Mark J. Dryden, Suresh Ratnam, Sherry Pierce, Stefan Faderl, Francis Giles, Hagop M. Kantarjian, Guillermo Garcia-Manero*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

Acute promyelocytic leukemia (APL) is characterized by the presence of the t(15;17) translocation, resulting in the PML-RAR fusion protein. Standard treatment consists of the combination of all-trans retinoic acid (ATRA) with an anthracycline that results in complete remission (CR) rates in excess of 90%. Recently, several new agents have been shown to have clinical activity in APL. These include a liposomal formulation of ATRA (lipo-ATRA), and gemtuzumab ozogamicin (GO). Herein, we report a patient with APL who relapsed with extramedullary disease 2.5 years after lipo-ATRA therapy and was successfully treated with the sequence of A2O3, ATRA, and GO and we summarize our experience with patients with isolated extramedullary relapse in APL.

Original languageEnglish (US)
Pages (from-to)991-994
Number of pages4
JournalLeukemia Research
Volume28
Issue number9
DOIs
StatePublished - Sep 1 2004

Keywords

  • APL
  • ATRA
  • Extramedullary relapse

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Extramedullary relapse in a patient with acute promyelocytic leukemia: Successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies'. Together they form a unique fingerprint.

Cite this